Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.51 |
| ▸ | PDE4A | P27815 | 4/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27951573 | 0.87 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL6051027 | 0.76 | ALOX15 (0.45) | MAPTALOX15GFERADAM17LMNA | |
| SCHEMBL6051031 | 0.75 | ALOX15 (0.46) | NPC1MAPTRAB9ASMN1; SMN2ALOX15 | |
| SCHEMBL15270512 | 0.75 | PARP10 (0.46) | ALOX15GFERADAM17KMT2A | |
| SCHEMBL29115173 | 0.74 | NPSR1 (0.63) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL6073145 | 0.73 | JAK2 (0.34) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL2889923 | 0.72 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084849 | 0.72 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30614148 | 0.70 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL717213 | 0.70 | PDE4D (0.66) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086653-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060094658-A1 | Method and compositions for the treatment of gastrointestinal disorders | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2006-05-04 | — | — | US | disclosed |
| WO-2005087797-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-6531493-B1 | 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis | ALTANA PHARMA AG (DE) | 2003-03-11 | — | — | US | disclosed |
| US-6498173-B1 | TREATMENT OF DISEASES BASED ON ACUTE OR CHRONIC OBSTRUCTION OF VESSELS AND/OR BRONCHI AND/OR INFLAMMATION | ALTANA PHARMA AG (DE) | 2002-12-24 | — | — | US | disclosed |
| US-6436970-B1 | POWDERS COMPRISING HETEROCYCLIC IMINES, PROTEIN-B AND/OR-C, USED FOR THE PROPHYLAXIS OF INFANT OR ADULT RESPIRATORY DISTRESS SYNDROME | BYK GULDEN LOMBERG CHEMISCHE FEBRIK GMBH (DE) | 2002-08-20 | — | — | US | disclosed |
| US-6333354-B1 | Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | PDE4D 15/4885PDE4B 22/4885PDE4A 12/4885 |
| US-20060094658-A1 | Method and compositions for the treatment of gastrointestinal disorders | GRPR, GCGR, GIPR | PDE4D 477/4885PDE4B 399/4885PDE4A 423/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE4D 15/4885PDE4B 22/4885PDE4A 12/4885 |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | PDE4D 793/4885PDE4B 528/4885PDE4A 408/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE4D 15/4885PDE4B 22/4885PDE4A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.